Certara (NASDAQ:CERT) Issues FY 2026 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.440-0.480 for the period, compared to the consensus estimate of 0.470. The company issued revenue guidance of $418.8 million-$435.6 million, compared to the consensus revenue estimate of $446.5 million.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. BMO Capital Markets started coverage on Certara in a report on Thursday, November 13th. They set a “market perform” rating and a $9.00 price target for the company. Wall Street Zen cut shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. Stephens reduced their target price on shares of Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, December 12th. Finally, Morgan Stanley lowered their target price on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Certara currently has an average rating of “Moderate Buy” and a consensus price target of $12.82.

Certara Stock Performance

CERT opened at $6.59 on Thursday. Certara has a 1-year low of $6.32 and a 1-year high of $15.38. The stock has a market cap of $1.05 billion, a P/E ratio of 94.14 and a beta of 1.47. The stock’s 50 day simple moving average is $8.44 and its 200 day simple moving average is $9.94. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09.

Certara (NASDAQ:CERT) last posted its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $103.65 million during the quarter, compared to analyst estimates of $103.23 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts anticipate that Certara will post 0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. grew its holdings in Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after buying an additional 2,870 shares during the last quarter. Osaic Holdings Inc. lifted its position in shares of Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after acquiring an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after acquiring an additional 4,930 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in Certara during the 2nd quarter worth about $83,000. Finally, Engineers Gate Manager LP acquired a new position in Certara in the 4th quarter valued at about $92,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.